Next Article in Journal
Comprehensive Expression Profiling and Functional Network Analysis of Porphyra-334, One Mycosporine-Like Amino Acid (MAA), in Human Keratinocyte Exposed with UV-radiation
Next Article in Special Issue
Investigating the Biosynthesis of Natural Products from Marine Proteobacteria: A Survey of Molecules and Strategies
Previous Article in Journal
Isolation and Selection of Microalgal Strains from Natural Water Sources in Viet Nam with Potential for Edible Oil Production
Previous Article in Special Issue
Interpreting Microbial Biosynthesis in the Genomic Age: Biological and Practical Considerations
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Bonnevillamides, Linear Heptapeptides Isolated from a Great Salt Lake-Derived Streptomyces sp.

1
Department of Medicinal Chemistry, University of Utah, Salt Lake City, UT 84112, USA
2
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
*
Author to whom correspondence should be addressed.
Mar. Drugs 2017, 15(7), 195; https://doi.org/10.3390/md15070195
Submission received: 2 June 2017 / Revised: 13 June 2017 / Accepted: 19 June 2017 / Published: 24 June 2017
(This article belongs to the Special Issue Connecting Marine Microbial Natural Products to Biosynthetic Pathways)

Abstract

:
Streptomyces sp. GSL-6B was isolated from sediment collected from the Great Salt Lake and investigation of its organic extract led to the isolation of three new linear heptapeptides, bonnevillamides A (1), B (2), and C (3). The bonnevillamides represent a new class of linear peptides featuring unprecedented non-proteinogenic amino acids. All three peptides contain the newly characterized bonnevillic acid moiety (3-(3,5-dichloro-4-methoxyphenyl)-2-hydroxyacrylic acid), as well as a heavily modified proline residue. Moreover, in bonnevillamide A, the terminal proline residue found in bonnevillamides B and C is replaced with 4-methyl-azetidine-2-carboxylic acid methyl ester. The structures of the three heptapeptides were elucidated by NMR, high-resolution electrospray ionization mass spectroscopy (HRESIMS), and LC-MS/MS, and the absolute configuration of all proteinogenic amino acid residues were determined by advanced Marfey’s method. Bonnevillamides A, B and C were evaluated for their effects on zebrafish embryo development. All three heptapeptides were shown to modulate heart growth and cardiac function, with bonnevillamide B having the most pronounced effect.

Graphical Abstract

1. Introduction

Natural products are medically useful compounds that play a pivotal role in drug discovery programs. However, with the increasing demand for new therapeutic agents, the discovery of new natural product scaffolds possessing novel modes of action are urgently needed. Biological pressures can influence the chemical diversity of secondary metabolites and microorganisms isolated from extreme environments, such as the deep sea [1], salterns [2,3], and hydrothermal vents [4,5] have been shown to be excellent producers of bioactive and structurally diverse small molecules [6]. Great Salt Lake, located in Utah, USA, is one of the world’s most hypersaline environments. Seawater has an average salinity of ~3.3%, whereas the Great Salt Lake ranges between 5% and 27% [7]. It has been reported that the Great Salt Lake is rich in halophilic and halotolerant microbial communities [7,8,9,10]. However, while there has been much success at discovering novel phylotypes, little is known about the Great Salt Lake’s potential as a resource for small molecule discovery.
Our current interest is aimed at evaluating the potential of halophilic and halotolerant bacteria isolated from the Great Salt Lake as new resources for the discovery of biologically active natural products. Sediment was collected from various locations in Farmington Bay, which is located in between Great Salt Lake’s North and South Arms, and processed to enrich for bacteria belonging to the order actinomycetes. HPLC and LC–MS were used to screen for secondary metabolites and it was observed that a new strain, Streptomyces sp. GSL-6B, produced a class of dichloro-substituted metabolites with a unique UV spectrum. Guided by UV characteristics and molecular weight, three linear heptapeptides were isolated. The bonnevillamides A–C (13) represent a new class of linear heptapeptides containing unprecedented amino acid residues (Figure 1). The three bonnevillamides contain bonnevillic acid (BVA) (3-(3,5-dichloro-4-methoxyphenyl)-2-hydroxyacrylic acid) and a heavily modified proline residue. Additionally, in place of a terminal proline residue, as observed in bonnevillamides B and C, bonnevillamide A contains 4-methyl-azetidine-2-carboxylic acid methyl ester (MACME). Herein, we report the isolation, structure elucidation and biological activity of 13.

2. Results and Discussion

After a nine day fermentation, Streptomyces sp. GSL-6B was harvested by centrifugation. Diaion HP-20 resin was incubated with the supernatant and then extracted with methanol to yield the crude supernatant extract, whereas the mycelium was extracted with acetone/water (70%/30%) to produce the mycelium crude extract. Using LC–MS, bonnevillamides A–C were detected in both the supernatant and mycelium extracts. The organic extracts were combined and fractionated by Sephadex LH-20 column chromatography and semi-preparative HPLC to afford compounds 13.

2.1. Structure Elucidation

Compound 1 was isolated as a light red solid. The isotopic ratio of 1 indicated the presence of two chlorine atoms and its molecular formula was determined as C45H66Cl2N6O14 using positive high-resolution electrospray ionization mass spectroscopy (HRESIMS) (m/z 985.4048 [M + H]+, calcd. for 985.4092). The peptide nature of 1 was suggested by the signal distribution observed in the 1H and 13C NMR spectra, which included exchangeable amide NH signals, amino acid α proton signals and seven carbonyl carbons. Careful interpretation of 1H-1H Correlation Spectroscopy (COSY), 1H-1H Total Correlation Spectroscopy (TOCSY) and gradient 1H-13C Heteronuclear Single Quantum Coherence (gHSQCAD) spectra allowed us to establish spin systems ascribable to threonine (Thr), valine (Val) and two leucine (Leu) residues (Figure 2). Unlike the other amino acids, the exchangeable amide proton in Val was not observed in the 1H NMR spectrum (Table 1). This signal was also not detected in the 2D Heteronuclear Multiple Bond Correlation (HMBC) and COSY correlations, suggesting the presence of an N, N-disubstituted amide. LC-MS/MS indicated a hydroxyl group was incorporated in place of the amide proton yielding a hydroxamic acid moiety. The highly modified 4-hydroxy-5-methylproline (HMPro) residue was identified as a new non-proteinogenic amino acid and its structure was deduced from TOCSY and HMBC experiments. MS/MS fragmentation and formula weight analysis showed that the C-4 hydroxyl group of HMPro in compound 1 is acetylated. Correlations from H3-6HMPro to C-5HMPro and C-4HMPro and from H2-3HMPro to C-4HMPro in the HMBC spectrum combined with the H-2HMPro/H2-3HMPro/H-4HMPro and H-5HMPro/H3-6HMProTOCSY correlations indicated that the methyl group is on C-5 and the acetyl group is located on C-4 (Figure 2). Irradiating δH 4.88 produced an NOE enhancement for H3-6HMPro and H-2HMPro indicating the co-facial positioning of the protons (Figure 3). Considering the final spin system of H-2MACME/H2-3MACME/H-4MACME/H3-5MACME and the nitrogen-containing nature of C-2MACME and C-4MACME (Figure 2), a 4-methyl-azetidine-2-carboxylic acid methyl ester residue was proposed. HMBC correlations from δH 3.67, δH 2.69 and δH 1.72 to the carbonyl carbon at δC 171.6 suggested the presence of a methyl ester appended onto C-2MACME, whereas correlations from δH 1.47 to the methylene δC 27.9 placed the methyl group on C-4MACME (Figure 2). A 1D Nuclear Overhauser Effect Spectroscopy (NOESY) was used to assign the relative configuration of MACME (Figure 3). Additionally, detailed analysis of the remaining signals, which were distributed to a symmetrical substituted benzene ring (δC 127.0, C-4BVA; δC 129.8, C-5 and C-5′BVA; δC 122.7, C-6 and C-6′BVA; δC 149.4, C-7BVA; δH 7.73, H-5 and H-5′BVA), an enolic double bond (δC 149.5, C-2BVA; δC 115.9, C-3BVA; δH 6.66, H-3BVA), a carbonyl carbon (δC 163.1, C-1BVA), and a methoxy group (δC 60.1, C-8BVA; δH3.67, H-8BVA) was used to characterize the bonnevillic acid (BVA) (3-(3,5-dichloro-4-methoxyphenyl)-2-hydroxyacrylic acid) building block. The BVA moiety was further supported by extensive HMBC correlations (Figure 2) and by comparing chemical shifts with those found in the aeruginosins [11,12].
Assignment of the amino acid sequence was carried out via a combination of HMBC, NOESY, Rotating Frame Nuclear Overhauser Effect Spectroscopy (ROESY) and MS/MS analysis. HMBC correlations from NHThr (δH 7.67) to C-1BVA and from NHLeu2 (δH 8.25) to C-1HMPro sequentially connected BVA to Thr and HMPro to Leu2 (Figure 2). NOESY correlations between NHThr and NHLeu1 and between NHLeu1 and H-5HMPro elongated the sequence to BVA-Thr-Leu-HMPro-Leu2 (Figure 2). Due to the presence of the methyl ester in the MACME residue, MACME was determined to be the terminal amino acid residue. Thus, the remaining Val residue must reside between Leu2 and MACME. The order of amino acids was further confirmed with a detailed analysis of LC–MS/MS data of 1 (Figure 4). This LC–MS/MS data of 1 provided further evidence for the presence of a hydroxamic acid moiety on Val and an acetylated HMPro residue. Consequently, the planar structure of 1 was elucidated as a linear heptapeptide with the sequence BVA-Thr-Leu1-O-Ac-HMPro-Leu2-N-OH-Val-MACME (Figure 1).
Compounds 2 and 3 were isolated as light red solids. Their molecular formulas were calculated as C42H62Cl2N6O13 and C44H64Cl2N6O14 by HRESIMS (m/z 929.3805 [M + H]+, calcd. for 929.3830; m/z 971.3926 [M + H]+, calcd. for 971.3936), respectively. Comparing the UV and 1H NMR spectra of 2 and 3 with those of 1 indicated that the compounds were analogs of 1. For compound 2, the MACME residue is replaced by Pro and the acetyl group observed on HMPro is absent. The substitution of Pro and loss of the acetyl moiety were supported by 1D and 2D NMR correlations (Figure 1 and Figure 2). The sequence of amino acid residues of 2 was assigned by HMBC, NOESY, ROESY and LC–MS/MS analysis (Figure 4). Comparing 1D and 2D NMR spectra between compounds 2 and 3 revealed that compound 3 was an OH-4HMPro acetylated derivative of 2. The 1D NOESY experiments confirmed that the HMPro residue in compounds 2 and 3 had the same relative configuration as that in compound 1 (Figure 3). Ultimately, the order of amino residues in compounds 2 and 3 were assigned as BVA-Thr-Leu1-HMPro-Leu2-N-OH-Val-Pro and BVA-Thr-Leu1-O-Ac-HMPro-Leu2-N-OH-Val-Pro, respectively.
To determine the absolute configurations of the proteinogenic amino acid residues in compounds 13, an advanced Marfey’s method was performed [13,14,15]. Each hydrolysate of 13 was divided into two fractions and derivatized with either 1-fluoro-2,4-dinitrophenyl-5-d,l-leucinamide (d,l-FDLA) or l-FDLA. The d,l-FDLA- or l-FDLA-derived products were monitored by LC-MS. For compounds 13, l-Thr, l-Leu, l-Val and l-Pro were deduced through retention time comparisons (Table S1). As no commercial standards are available for HMPro and MACME, their absolute configurations have not yet been determined.

2.2. Biosynthetic Proposal

The genome of Streptomyces sp. GSL-6B is currently being sequenced and when it is completed, the sequenced genome will be mined for the bonnevillamide biosynthetic cluster. Based on the linear arrangement of proteinogenic and non-proteinogenic amino acids, we propose that the bonnevillamides are assembled via a heptamodular non-ribosomal peptide synthetase (NRPS). NRPSs act as biosynthetic templates and typically assemble nonribosomal peptides in an assembly-line fashion. The catalytic domains embedded within the NRPS dictate the types of building blocks that are to be used for the assembly of a compound, as well as some modifications to the proteinogenic or non-proteinogenic substrates. Specialized monomers or building blocks required for the assembly of a natural product, such as non-proteinogenic amino acids, are generally synthesized from primary metabolites using a dedicated collection of genes located within the corresponding gene cluster [16]. The biosynthesis of compounds 13 is initiated with the unique BVA starter unit, which is most likely derived from tryosine. If this is the case, a tryosine ammonia lyase should be located in close proximity to the NRPS in which it catalyzes the elimination of ammonia to yield p-coumaric acid [17]. Additional modifications such as oxidation, halogenation and methylation would be required to produce the final BVA residue. The next NRPS module would incorporate a threonine residue, whereas modules 3, 4, 5 and 6 would incorporate leucine, proline, leucine and valine, respectively. Further inspection of module 6, as well as post-NRPS tailoring enzymes, will provide insight into the formation of the hydroxamic acid moiety on valine. Based on the structural similarities of the three bonnevillamides, we hypothesize that the compounds are biosynthesized by the same NRPS and that module 7 incorporates Pro. To form 1, post-NRPS tailoring enzymes may convert the terminal Pro residue to MACME and feeding studies with stable isotope-labeled amino acids will help elucidate the biosynthetic origin of this rare residue.

2.3. Bioactivity

Using the broth dilution method, compounds 13 were initially screened for antimicrobial activity. Unfortunately, no significant effect on the growth of Staphylococcus aureus (ATCC 126,000), Escherichia coli (D22 and ATCC 25,922), Pseudomonas aeruginosa (ATCC 27,853), Klebsiella pneumoniae (ATCC 13883), or Acinetobacter baummannii (ATCC BAA-1605) was observed for 13 at 32 µg/mL. The bonnevillamides were then evaluated for activity using a zebrafish embryonic development assay. Phenotypic changes were monitored using various concentrations of compound and at 100 μM, all three compounds had a pronounced effect on heart development and cardiac function compared to a DMSO control (Figure 5). A decreased heart rate, an enlarged pericardial sac and abnormal heart morphology were observed. Compound 2 was the most active, suggesting that the free hydroxyl found on HMPro may be responsible for its increased activity compared to 1 and 3. Additional studies are underway to identify the molecular target(s) of the bonnevillamides.

3. Materials and Methods

3.1. General Experimental Procedures

Optical rotations were measured on a Jasco DIP-370 polarimeter (Oklahoma City, OK, USA), UV spectra were recorded on a Perkin-Elmer Lamdba2 (Waltham, MA, USA) UV/vis spectrometer and NMR spectra were recorded on Varian INOVA (Palo Alto, CA, USA) 500 and 600 NMR spectrometers with 3 mm Nalorac MDBG probes. High resolution ESIMS was carried out on a Bruker (Billerica, MA, USA) maxis II ETD Q-TOF instrument and HPLC-MS/MS was recorded using a Micromass Q-TOF Micro Mass Spectrometer (Waters, Milford, MA, USA) in positive mode with an Agilent Eclipse XDB-C18 column (150 × 4.6 mm, 5 μm). Semi-preparative HPLC was performed using an ODS column (Thermo Scientific, Waltham, MA, USA, HYPERSIL GOLD 10 × 250 mm, 12 μm, 3 mL/min). Column chromatography was performed with Sephadex LH-20 (GE Healthcare Bio-Sciences AB, Uppsala, Sweden).

3.2. Isolation and Fermentation of Streptomyces sp. GSL-6B

Streptomyces sp. GSL-6B was isolated from sediment collected from Farmington Bay in the Great Salt Lake, UT, USA. Sediment samples were collected at a depth of 0.6 m and placed in sterile 50 mL conical tubes and kept cool until processed. In a biological safety cabinet, 20 mL of wet sediment was dried for 48 h. Approximately 0.5 g of dried sediment was added to yeast-peptone-mannitol (YPM) agar (4 g/L mannitol, 2 g/L yeast extract, 2 g/L peptone, and 42 g/L Instant Ocean Aquarium Sea Salt Mixture, Spectrum Brands, USA) and incubated at 30 °C for up to 90 days. Bacterial colonies were subcultured on YPM until pure isolates were obtained. 16S sequencing was used to identify GSL-6B as a Streptomyces sp. (GenBank accession number for the partial 16S rDNA sequence is MF288649). Streptomyces sp. GSL-6B was cultured at 28 °C for four days with constant shaking at 160 rpm in 125 mL Erlenmeyer flasks containing 50 mL of marine-based fermentation media (glucose (20.0 g/L), beef extract (3.0 g/L), yeast extract (10.0 g/L), soluble starch (10.0 g/L), K2HPO4 (0.5 g/L), MgSO4 (0.5 g/L), CaCO3 (2.0 g/L), and artificial sea salt (33.0 g/L, Instant Ocean Aquarium Sea Salt Mixture) at pH = 7.0). After five days, 20 2.8 L Fernbach flasks containing 1 L of marine-based fermentation media were inoculated using 1% of the seed cultures and incubated at 28 °C for nine days with constant shaking at 160 rpm.

3.3. Extraction and Isolation

After 9 days of fermentation, 20 L of broth was centrifuged and the supernatant was incubated with HP-20 resin (20 g/L) with shaking at 120 rpm for 2 h. The resin was then filtered through miracloth, washed three times with water (200 mL aliquots) to remove salts and extracted three times with methanol (300 mL aliquots) to yield the supernatant crude extract. The mycelium was extracted three times with 70% acetone (500 mL total volume) and concentrated in vacuo. To the ~1 mL of oil, 300 mL of water was added and partitioned with an equal volume of ethyl acetate to yield the mycelium crude extract. By LC–MS, it was observed that the bonnevillamides were found in both the supernatant and mycelium. The crude extracts were combined, concentrated in vacuo and fractionated with a SephadexLH-20 column (60 cm (length) × 1.5 cm (diameter)) using 50 mL aliquots of 100% MeOH. Based on mass spectroscopy and UV, fraction 1 contained the targeted compounds and was subjected to further purification via semi-preparative HPLC. A Hypersil Gold 10 × 250 mm C18 column was used at a flow rate of 3 mL/min and an isocratic condition of 65% MeOH:H2O with 0.1% TFA to afford compounds 1 (5.0 mg, tR = 16.1 min), 2 (5.1 mg, tR = 16.8 min), and 3 (3.0 mg, tR = 17.2 min).
Bonnevillamide A (1): light red solid; [α] D 20 −30° (c 0.1, CHCl3); UV (MeOH) λmax (log ε) 236 (3.00), 295 (3.96) nm; 1H and 13C NMR data, Table 1 and Supporting Information; HRESIMS m/z 985.4048 [M + H]+ (calcd. for C45H67Cl2N6O14, 985.4092).
Bonnevillamide B (2): light red solid; [α] D 20 −25° (c 0.1, CHCl3); UV (MeOH) λmax (log ε) 236 (3.05), 294 (4.06) nm; 1H and 13C NMR data, Table 1 and Supporting Information; HRESIMS m/z 929.3805 [M + H]+ (calcd. for C42H63Cl2N6O13, 929.3830).
Bonnevillamide C (3): light red solid; [α] D 20 −40° (c 0.1, CHCl3); UV (MeOH) λmax (log ε) 235 (3.07), 295 (4.09) nm; 1H and 13C NMR data, Table 1 and Supporting Information; HRESIMS m/z 971.3926 [M + H]+ (calcd. for C44H65Cl2N6O14, 971.3936).

3.4. Advanced Marfey’s Anslysis

Each peptide (~0.2 mg) was dissolved in 500 µL 6 N·HCl and heated in an ampule for 17 h at 110 °C. The hydrolysate was evaporated to dryness in vacuo and re-dissolved in 100 μL H2O. The solution was divided into two fractions and to each fraction, 20 μL 1 N·NaHCO3 and 100 μL of either d,l-FDLA or l-FDLA (1% solution in acetone) was added. The mixture was heated for 50 min at 40 °C, quenched by adding 20 μL 1N·HCl and dried in vacuo. The residue was dissolved in 1:1 CH3CN-H2O and analyzed by LC–MS. Separation of the residues was carried out using an Agilent (Santa Clara, CA, USA) Eclipse XDB-C18 column (5 μm, 4.6 × 150 mm) at a flow rate of 0.5 mL/min with a linear gradient of 5% to 100% CH3CN in 0.1% formic acid over 45 min. Absolute configurations of the proteinogenic amino acids were determined by comparing the retention times of the d,l- and l-FDLA derivatives, which were identified by MS. Retention times of the d,l-FDLA amino acid derivatives were 22.03 and 24.57 min (Thr), 27.94 and 32.03 min (Leu), 26.69 and 29.95 min (Val), and 24.41 and 26.00 min (Pro) (Figures S33‒S35 and Table S1). The retention times of the l-FDLA amino acid derivatives were 22.08 min (Thr), 28.03 min (Leu), 26.69 min (Val), and 24.35 min (Pro) (Figures S33‒S35 and Table S1).

3.5. Zebrafish Assays

Animals were maintained and embryos were obtained according to standard fish husbandry protocols. Fertilized eggs were collected from group mating of TuAB zebrafish and stored in E3 media at 28 °C until 2 hpf. At 2 hpf, groups of ~5 embryos were distributed into the wells of flat-bottom 96 well plates filled with E3 media (400 μL) and DMSO, 1, 2, or 3 were added at the indicated concentrations. The plates of embryos were then incubated at 28 °C. All zebrafish protocols were approved by the Institutional Animal Care and Use Committee at the University of Utah.

3.6. Heartrate Analysis

The amount of time required for the heart of a 60 hpf zebrafish embryo to beat 20 times was measured manually, by monitoring the heart of each embryo under a Zeiss SteREO Discovery V8 microscope (Zeiss, Jena, Germany), and used to extrapolate the number of heart beats per minute for a single zebrafish embryo.

4. Conclusions

Biological pressures can influence the chemical diversity of secondary metabolites and it has been shown that microorganisms isolated from extreme environments often produce molecules not observed in their terrestrial counterparts. A chemical investigation of Streptomyces sp. GSL-6B, isolated from sediment collected from the Great Salt Lake, led to the isolation of bonnevillamides A–C (13). The bonnevillamides represent a new class of linear heptapetides featuring novel amino acid residues. All three compounds contain the newly characterized bonnevillic acid building block, as well as a heavily modified proline residue. Additionally, while bonnevillamide B (2) and C (3) contain a terminal proline residue, bonnevillamide A (1) contains an extremely rare 4-methyl-azetidine-2-carboxylic acid methyl ester moiety. The three peptides were evaluated for their effects on zebrafish embryo development and shown to modulate heart growth and cardiac function, with bonnevillamide B (2) having the most pronounced effect. Preliminary structure–activity relationship data suggests that the free hydroxyl found on the 4-hydroxy-5-methylproline residue in 2 appears to be a key structural feature for the observed activity. All three structures were characterized by 1D and 2D NMR spectroscopy and absolute configuration of the proteinogenic amino acid residues was determined using the advanced Marfey’s method.

Supplementary Materials

The following are available online at www.mdpi.com/1660-3397/15/7/195/s1, Figure S1: UV spectra of compounds 13; Figures S2–S11: 1H NMR,13C NMR, gHSQCAD , gHMBCAD, TOCSY, COSY, ROESY, NOESY and 1D NOE of bonnevillamide A (1) in DMSO-d6; Figures S12–S13: HRESIMS/MS and HR(+)ESIMS of bonnevillamide A (1); Figures S14–S22: 1H NMR,13C NMR, gHSQCAD, gHMBCAD, TOCSY, COSY, ROESY, NOESY and 1D NOE of bonnevillamide B (2) in DMSO-d6; Figures S23–S24: HRESIMS/MS and HR(+)ESIMS of bonnevillamide B (2); Figures S25–S31: 1H NMR, gHSQCAD, gHSQCAD, TOCSY, COSY, ROESY, and NOESY spectrum of bonnevillamide C (3) in DMSO-d6; Figure S32: HR(+)ESIMS of bonnevillamide C (3); Figure S33: Advanced Marfey’s analysis of bonnevillamide A (1); Figure S34: Advanced Marfey’s analysis of bonnevillamide B (2); Figure S35: Advanced Marfey’s analysis of bonnevillamide C (3); Table S1: Retention times of amino acid derivatives used in advanced Marfey’s analysis.

Acknowledgments

This work was supported by the Department of Medicinal Chemistry Start-Up Funds (Jaclyn M. Winter). We also thank Christopher Kauffman, Stephen Bell, WenjiaGu and Aaron Rodgers (University of Utah) for help with collecting and processing the sediment from the Great Salt Lake, Chad Testa (University of Utah) for performing the antimicrobial activity screening and Jack Skalicky and Zhenjian Lin (University of Utah) for NMR instrument usage and helpful discussions.

Author Contributions

Guangwei Wu and Jaclyn M. Winter conceived and designed the experiments; Guangwei Wu and Jason R. Nielson performed the experiments; Guangwei Wu, Jason R. Nielson, Randall T. Peterson, and Jaclyn M. Winter analyzed the data; Guangwei Wu, Jason R. Nielson, Randall T. Peterson, and Jaclyn M. Winter contributed reagents/materials/analysis tools; Guangwei Wu, Jason R. Nielson, Randall T. Peterson, and Jaclyn M. Winter wrote the paper.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Skropeta, D. Deep-sea natural products. Nat. Prod. Rep. 2008, 25, 1131–1166. [Google Scholar] [CrossRef] [PubMed]
  2. Kim, S.H.; Shin, Y.; Lee, S.H.; Oh, K.B.; Lee, S.K.; Shin, J.; Oh, D.C. Salternamides A–D from a Halophilic Streptomyces sp. Actinobacterium. J. Nat. Prod. 2015, 78, 836–843. [Google Scholar] [CrossRef] [PubMed]
  3. Kim, S.H.; Ha, T.K.; Oh, W.K.; Shin, J.; Oh, D.C. Antiviral Indolosesquiterpenoid Xiamycins C–E from a Halophilic Actinomycete. J. Nat. Prod. 2016, 79, 51–58. [Google Scholar] [CrossRef] [PubMed]
  4. Thornburg, C.C.; Zabriskie, T.M.; McPhail, K.L. Deep-sea hydrothermal vents: Potential hot spots for natural products discovery? J. Nat. Prod. 2010, 73, 489–499. [Google Scholar] [CrossRef] [PubMed]
  5. Pettit, R.K. Culturability and secondary metabolite diversity of extreme microbes: Expanding contribution of deep sea and deep-sea vent microbes to natural product discovery. Mar. Biotechnol. 2011, 13, 1–11. [Google Scholar] [CrossRef] [PubMed]
  6. Wilson, Z.E.; Brimble, M.A. Molecules derived from the extremes of life. Nat. Prod. Rep. 2009, 26, 44–71. [Google Scholar] [CrossRef] [PubMed]
  7. Tazi, L.; Breakwell, D.P.; Harker, A.R.; Crandall, K.A. Life in extreme environments: Microbial diversity in Great Salt Lake, Utah. Extremophiles 2014, 18, 525–535. [Google Scholar] [CrossRef] [PubMed]
  8. Parnell, J.J.; Rompato, G.; Crowl, T.A.; Weimer, B.C.; Pfrender, M.E. Phylogenetic distance in Great Salt Lake microbial communities. Aquat. Microb. Ecol. 2011, 64, 267–273. [Google Scholar] [CrossRef]
  9. Almeida-Dalmet, S.; Sikaroodi, M.; Gillevet, P.M.; Litchfield, C.D.; Baxter, B.K. Temporal Study of the Microbial Diversity of the North Arm of Great Salt Lake, Utah, U.S. Microorganisms 2015, 3, 310–326. [Google Scholar] [CrossRef] [PubMed]
  10. Meuser, J.E.; Baxter, B.K.; Spear, J.R.; Peters, J.W.; Posewitz, M.C.; Boyd, E.S. Contrasting patterns of community assembly in the stratified water column of Great Salt Lake, Utah. Microb. Ecol. 2013, 66, 268–280. [Google Scholar] [CrossRef] [PubMed]
  11. Elkobi-Peer, S.; Faigenbaum, R.; Carmeli, S. Bromine- and chlorine-containing aeruginosins from Microcystis aeruginosa bloom material collected in Kibbutz Geva, Israel. J. Nat. Prod. 2012, 75, 2144–2151. [Google Scholar] [CrossRef] [PubMed]
  12. Elkobi-Peer, S.; Singh, R.K.; Mohapatra, T.M.; Tiwari, S.P.; Carmeli, S. Aeruginosins from a Microcystis sp. bloom material collected in Varanasi, India. J. Nat. Prod. 2013, 76, 1187–1190. [Google Scholar] [CrossRef] [PubMed]
  13. Fujii, K.; Ikai, Y.; Mayumi, T.; Oka, H.; Suzuki, M.; Harada, K. A nonempirical method using LC/MS for determination of the absolute configuration of constituent amino acids in a peptide: Elucidation of limitations of Marfey’s method and of its separation mechanism. Anal. Chem. 1997, 69, 3346–3352. [Google Scholar] [CrossRef]
  14. Fujii, K.; Ikai, Y.; Oka, H.; Suzuki, M.; Harada, K. A nonempirical method using LC/MS for determination of the absolute configuration of constituent amino acids in a peptide: Combination of Marfey's method with mass spectrometry and its practical application. Anal. Chem. 1997, 69, 5146–5151. [Google Scholar] [CrossRef]
  15. Lin, Z.; Flores, M.; Forteza, I.; Henriksen, N.M.; Concepcion, G.P.; Rosenberg, G.; Haygood, M.G.; Olivera, B.M.; Light, A.R.; Cheatham, T.E.; et al. Totopotensamides, polyketide-cyclic peptide hybrids from a mollusk-associated bacterium Streptomyces sp. J. Nat. Prod. 2012, 75, 644–649. [Google Scholar] [CrossRef] [PubMed]
  16. Fischbach, M.A.; Walsh, C.T. Assembly-line enzymology for polyketide and nonribosomal Peptide antibiotics: Logic, machinery, and mechanisms. Chem. Rev. 2006, 106, 3468–3496. [Google Scholar] [CrossRef] [PubMed]
  17. Kyndt, J.A.; Meyer, T.E.; Cusanovich, M.A.; Van Beeumen, J.J. Characterization of a bacterial tyrosine ammonia lyase, a biosynthetic enzyme for the photoactive yellow protein. FEBS Lett. 2002, 512, 240–244. [Google Scholar] [CrossRef]
Figure 1. Structures of bonnevillamide A (1), B (2) and C (3).
Figure 1. Structures of bonnevillamide A (1), B (2) and C (3).
Marinedrugs 15 00195 g001
Figure 2. The 2D NMR correlations of compounds 13.
Figure 2. The 2D NMR correlations of compounds 13.
Marinedrugs 15 00195 g002
Figure 3. Stick models of 4-methyl-azetidine-2-carboxylic acid methyl ester (MACME) and 4-hydroxy-5-methylproline (HMPro) residues in 13. Key 1D NOE correlations are shown as black arrows. Atom definitions: red, oxygen; blue, nitrogen; gray, carbon; white, hydrogen.
Figure 3. Stick models of 4-methyl-azetidine-2-carboxylic acid methyl ester (MACME) and 4-hydroxy-5-methylproline (HMPro) residues in 13. Key 1D NOE correlations are shown as black arrows. Atom definitions: red, oxygen; blue, nitrogen; gray, carbon; white, hydrogen.
Marinedrugs 15 00195 g003
Figure 4. LC–MS/MS data for 1 and 2.
Figure 4. LC–MS/MS data for 1 and 2.
Marinedrugs 15 00195 g004
Figure 5. Evaluating the activity of compounds 13 using a zebrafish embryonic development assay: (a) Quantification of 60 hpf zebrafish embryo heartrate. Each square, triangle, circle or diamond represents a single fish and shape definitions are: DMSO, square; 1, triangle; 2, circle; and 3, diamond. Statistics from Student’s t-test (compared to 1% DMSO-treated samples): * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001; (b) Representative images of 75 hpf zebrafish treated with the indicated bonnevillamides; (c) Magnified view of panel (b) highlighting the pericardial edema and abnormal heart morphology.
Figure 5. Evaluating the activity of compounds 13 using a zebrafish embryonic development assay: (a) Quantification of 60 hpf zebrafish embryo heartrate. Each square, triangle, circle or diamond represents a single fish and shape definitions are: DMSO, square; 1, triangle; 2, circle; and 3, diamond. Statistics from Student’s t-test (compared to 1% DMSO-treated samples): * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001; (b) Representative images of 75 hpf zebrafish treated with the indicated bonnevillamides; (c) Magnified view of panel (b) highlighting the pericardial edema and abnormal heart morphology.
Marinedrugs 15 00195 g005
Table 1. NMR data of 13 in DMSO-d6.
Table 1. NMR data of 13 in DMSO-d6.
ResiduePositionBonnevillamide A (1)Bonnevillamide B (2)Bonnevillamide C (3)
δC aδH (J in Hz) bδC aδH (J in Hz) bδC cδH (J in Hz) b
BVA1163.1 C-163.1 C-163.1 C-
2149.5 C-149.5 C-149.5 C-
3115.9 CH6.66, s116.1 CH6.66, s115.9 CH6.67, s
4127.0 C-126.9 C-d-
5/5′129.8 CH7.73, s129.8 CH7.70, s129.7 CH7.73, s
6/6′122.7 C-122.7 C-122.6 C-
7149.4 C-149.5 C-149.5 C-
860.1 CH33.67, s59.5 CH33.65, s59.4 CH33.67, s
Thr1170.2 C-169.8 C-170.2 C-
259.1 CH4.26, dd (4.8, 8.6)58.8 CH4.30, m59.1 CH4.27, dd (5.0, 8.6)
367.2 CH3.93, m67.5 CH3.97, m67.1 CH3.97, m
420.8 CH31.05, d (6.4)20.1 CH31.02, d (5.2)20.7 CH31.05, d (6.3)
NH-7.67, d (8.6)-7.65, d (7.4)-7.68, d (8.5)
Leu 11173.8 C-173.7 C-d-
248.0 CH4.98, m47.9 CH4.95, m48.6 CH4.49, m
340.1 CH21.37, m; 1.52, m40.5 CH21.34, m; 1.46, m41.4 CH21.31, m; 1.62, m
424.4 CH1.66, m24.7 CH1.64, m24.7 CH1.62, m
522.1 CH30.83, overlap23.6 CH30.85, overlap21.5 CH30.82, overlap
622.4 CH30.83, overlap22.2 CH30.83, overlap23.7 CH30.89, d (6.9)
NH-7.83, d (8.4) 7.76, d (6.8)-8.26, d (8.0)
HMPro1170.7 C-171.3 C-170.7 C-
258.4 CH4.43, overlap58.8 CH4.44, m58.4 CH4.51, overlap
332.1 CH22.15, m35.2 CH21.92, m; 1.98, m32.2 CH22.16, m; 2.22 m
478.5 CH4.88, m75.3 CH3.90, brs78.5 CH4.89, d
560.1 CH4.49, m62.4 CH4.01, m60.1 CH4.49, overlap
619.1 CH31.18, d (6.8)19.3 CH31.10, d (6.7)19.1 CH31.18, d (6.9)
7170.5 C---170.5 C-
821.3 CH31.99, s--21.4 CH32.00, s
Leu 21171.2 C-167.3 C-d-
248.6 CH4.49, m48.3 CH4.66, m48.1 CH4.97, m
341.3 CH21.31, m; 1.62, m41.9 CH21.38, m; 1.47, m40.3 CH21.37, m; 1.50, m
424.7 CH1.62, m24.5 CH1.57, m24.5 CH1.67, m
521.5 CH30.82, overlap23.8 CH30.84, overlap22.1 CH30.83, overlap
623.7 CH30.88, d (6.9)21.5 CH30.80, overlap22.3 CH30.83, overlap
NH-8.25, d (8.0)-8.20, d (7.6)-7.82, d (8.6)
N-OH-Val1168.3 C-167.3 C-167.3 C-
261.2 CH4.43, m62.4 CH4.66, m62.4 CH4.70, d (10.5)
326.1 CH22.31, m26.8 CH2.30, m26.9 CH22.34, m
418.9 CH30.77, d (6.7)19.0 CH30.76, d (7.0)19.0 CH30.79, d (6.7)
519.7 CH30.84, overlap19.5 CH30.83, overlap19.5 CH30.88, d (6.6)
MACME/Pro1171.6 C-171.1 C-d-
256.2 CH4.49, m59.1 CH4.18, m59.2 CH4.21, dd (4.6, 8.7)
327.9 CH22.69, m; 1.72, m29.2 CH21.78, m; 2.10, m29.2 CH21.83, m; 2.14, m
457.3 CH4.36, m25.0 CH21.80, m; 1.90, m24.9 CH21.91, m; 1.83, m
522.4 CH31.47, d (6.2)46.9 CH23.47, m46.9 CH23.50, m
652.4 CH33.67, s----
a, 13C spectrum was recorded in DMSO-d6 in 500 MHz NMR; b, 1H spectrum was recorded in DMSO-d6 in 600 MHz NMR; c, The carbon chemical shifts were deduced by HSQC and HMBC experiments; d, Carbon signals were not detected.

Share and Cite

MDPI and ACS Style

Wu, G.; Nielson, J.R.; Peterson, R.T.; Winter, J.M. Bonnevillamides, Linear Heptapeptides Isolated from a Great Salt Lake-Derived Streptomyces sp. Mar. Drugs 2017, 15, 195. https://doi.org/10.3390/md15070195

AMA Style

Wu G, Nielson JR, Peterson RT, Winter JM. Bonnevillamides, Linear Heptapeptides Isolated from a Great Salt Lake-Derived Streptomyces sp. Marine Drugs. 2017; 15(7):195. https://doi.org/10.3390/md15070195

Chicago/Turabian Style

Wu, Guangwei, Jason R. Nielson, Randall T. Peterson, and Jaclyn M. Winter. 2017. "Bonnevillamides, Linear Heptapeptides Isolated from a Great Salt Lake-Derived Streptomyces sp." Marine Drugs 15, no. 7: 195. https://doi.org/10.3390/md15070195

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop